incrementalNew research

Alarmin-targeting biologics in development for CRSwNP

Chronic Rhinosinusitis with Nasal Polyps →

Summary

Tezepelumab (anti-TSLP) and itepekimab (anti-IL-33) are in phase 2/3 trials for CRSwNP, targeting upstream epithelial alarmins as a novel therapeutic approach.

Related genes

TSLPRegulatory SNPs
TSLP variants influence epithelial alarmin production. TSLP activates dendritic cells to drive Th2 polarisation and directly activates ILC2s.

More from Chronic Rhinosinusitis with Nasal Polyps

significantNew research

Head-to-head biologic comparison studies beginning

significantTreatment update

Benralizumab (anti-IL-5Rα) FDA-approved for CRSwNP (2024)

ID: crswnp-update-2Type: new_researchImpact: incremental